Single answer
Is AlloVir Inc (ALVR) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
What is the conclusion?
Right now our advanced algorithms say:
Do analysts agree?
We compare consensus targets with today's price.
No analyst target data available for this ticker.
Company snapshot
A quick overview of the business and its public profile.
Allovir Inc a clinicalstage cell therapy company engages in the research and development of allogeneic offtheshelf multivirus specific T cell VST therapies to prevent and treat devastating viralassociated diseases The companys lead product is posoleucel an allogeneic offtheshelf VST therapy to treat BK virus cytomegalovirus adenovirus EpsteinBarr virus human herpesvirus 6 and JC virus Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus influenza parainfluenza virus and human metapneumovirus ALVR109 to treat SARSCoV2 and COVID19 ALVR107 for treating hepatitis B and ALVR108 The company was formerly known as ViraCyte Inc and changed its name to Allovir Inc in May 2019 Allovir Inc was founded in 2013 and is based in Waltham Massachusetts
Website: httpswwwallovircom
Rates and inflation backdrop
US inflation for September 2025 was 0.31%. Over the last 12 months, inflation is 3.02%. The 10-year yield is 4.12 and is down -0.1000 over the last 30 days.
Inflation sensitivity
Debt ratio: 0.02. Cash flow to debt ratio: -22.58. Net profit margin: 0.00%. Inflation risk score: medium (0.60/1).
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
Yes, the average daily trading liquidity for AlloVir Inc is $1M. You should therefore be able to get in and out of your positions relatively fast.
10-year return check
We cannot find data for AlloVir Inc 10 years ago, but if you had invested on 2020-07-30 when the price was $25.39, you would have made a loss of $15.58 per share or 61.36%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.
No analyst target data available for this ticker.